You are here

GEOVAX, INC.

Company Information
Address
1900 LAKE PARK DR STE 380
SMYRNA, GA 30080-7648
United States


http://www.geovax.com

Information

UEI: CEF5ULT44LF5

# of Employees: 17


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19

    Amount: $299,927.00

    PROJECT SUMMARY With unprecedented speed and scale, SARS-CoV-2 has caused a deadly global pandemic. A safe and effective vaccine to control this new pathogen is desperately needed. To address this nee ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  2. Construction and efficacy testing of novel recombinant vaccine designs for eliciting both broadly neutralizing antibodies and T cells against Lassa virus

    Amount: $299,820.00

    PROJECT SUMMARY GeoVaxa clinical stage biotechnology company focusing on vaccine development against infectious diseases and cancerseeks to build on its successful vaccine candidate against Lassa viru ...

    SBIRPhase I2018Department of Health and Human Services National Institutes of Health
  3. Advanced Preclinical Testing of a Novel Recombinant Vaccine Against Zika Virus

    Amount: $600,000.00

    PROJECT SUMMARY ABSTRACT The recent acceleration in incidence and intensity of human disease caused by Zika virusZIKVinfection has prompted an international outcry for safe and effective countermeasur ...

    SBIRPhase I2017Department of Health and Human Services National Institutes of Health
  4. Enhancing protective antibody responses for a DNA MVA HIV vaccine

    Amount: $1,398,615.00

    DESCRIPTION provided by applicant The proposed work addresses a pivotal study for decisions on the form of the GeoVax Clade B HIV vaccine GOVX B to be taken into efficacy trials GOVX B is a ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  5. Directed Lineage Immunizations for Eliciting Broadly Neutralizing Antibody

    Amount: $593,623.00

    DESCRIPTION provided by applicant The proposed project Directed Lineage Immunizations for Eliciting Broadly Neutralizing Antibody tests the directed lineage D L approach to HIV vaccination usin ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  6. Drug Resistant HIV: Novel Target Validation and Small Molecule Lead Discovery

    Amount: $566,331.00

    DESCRIPTION (provided by applicant): HIV/AIDS remains a major health problem and there is a need for effective and durable HIV vaccines. Establishing potent and durable antibodies (Ab) that have neutr ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health
  7. PROCESS ENGINEERING HIV-BASED RECOMBINANT MVA VACCINE

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Development of process optimization for production of the recombinant modified vaccinia Ankara (rMVA) virus booster component of a novel multiprotein-expressing D ...

    SBIRPhase I2002Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government